Patents by Inventor David Corey

David Corey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Treating Cag Repeat Diseases
    Publication number: 20240425856
    Abstract: The disclosure relates to compositions and methods for the production and therapeutic use of inhibitory double stranded RNAs.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 26, 2024
    Inventors: Philip J. Jensik, Keith T. Gagnon, David Corey, Eleonora de Klerk, Megan Blewett, Melissa A. Kotterman
  • COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20240229029
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Application
    Filed: September 20, 2023
    Publication date: July 11, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Liande LI
  • ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
    Publication number: 20240141348
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Application
    Filed: October 19, 2023
    Publication date: May 2, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Jiaxin HU
  • COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20240132889
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 25, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Liande LI
  • Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat
    Patent number: 11840690
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: December 12, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: David Corey, Jiaxin Hu
  • Compositions and methods for treatment of Friedreich's Ataxia
    Patent number: 11795457
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: October 24, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: David Corey, Liande Li
  • COMPOUNDS AND METHODS FOR MODULATING C90RF72
    Publication number: 20230020192
    Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.
    Type: Application
    Filed: February 4, 2022
    Publication date: January 19, 2023
    Applicants: IONIS PHARMACEUTICALS, INC., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thazha P. PRAKASH, Frank RIGO, David COREY
  • Modulation of frataxin expression
    Patent number: 11459564
    Abstract: Certain embodiments are directed to methods and compounds for increasing FXN. Such methods and compounds are useful for increasing expression of FXN in cells and animals.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 4, 2022
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Rigo, Thazha P. Prakash, David Corey
  • ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
    Publication number: 20220073918
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Jiaxin HU
  • Compounds and methods for modulating C90RF72
    Patent number: 11260073
    Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 1, 2022
    Assignees: IONIS PHARMACEUTICALS, INC., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thazha P. Prakash, Frank Rigo, David Corey
  • COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20220017903
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 20, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Liande LI
  • MODULATION OF FRATAXIN EXPRESSION
    Publication number: 20210087559
    Abstract: Certain embodiments are directed to methods and compounds for increasing FXN. Such methods and compounds are useful for increasing expression of FXN in cells and animals.
    Type: Application
    Filed: December 21, 2018
    Publication date: March 25, 2021
    Inventors: Frank RIGO, Thazha P. PRAKASH, David COREY
  • ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
    Publication number: 20200208154
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Application
    Filed: January 10, 2020
    Publication date: July 2, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David COREY, Jiaxin HU
  • Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
    Patent number: 10538762
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 21, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David Corey, Jiaxin Hu
  • Methods and compounds useful in conditions related to repeat expansion
    Patent number: 10435430
    Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 8, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thazha P. Prakash, Jiaxin Hu, Jing Liu, Dongbo Yu, David Corey, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20190002876
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Application
    Filed: December 8, 2015
    Publication date: January 3, 2019
    Inventors: David COREY, Liande LI
  • COMPOUNDS AND METHODS FOR MODULATING C90RF72
    Publication number: 20180318330
    Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Inventors: Thazha P. PRAKASH, Frank RIGO, David COREY
  • Methods and compounds useful in conditions related to repeat expansion
    Patent number: 9976138
    Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: May 22, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, David Corey, Dongbo Yu
  • ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
    Publication number: 20170233735
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).
    Type: Application
    Filed: October 8, 2015
    Publication date: August 17, 2017
    Inventors: David COREY, Jiaxin HU
  • METHODS AND COMPOUNDS USEFUL IN CONDITIONS RELATED TO REPEAT EXPANSION
    Publication number: 20160159846
    Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
    Type: Application
    Filed: July 31, 2014
    Publication date: June 9, 2016
    Applicants: Ionis Pharmaceuticals, Inc., Board of Regents of the University of Texas System
    Inventors: Thazha P. Prakash, Jiaxin Hu, Jing Liu, Dongbo Yu, David Corey, Eric E. Swayze